Cardiac Imaging

While cardiac ultrasound is the widely used imaging modality for heart assessments, computed tomography (CT), magnetic resonance imaging (MRI) and nuclear imaging are also used and are often complimentary, each offering specific details about the heart other modalities cannot. For this reason the clinical question being asked often determines the imaging test that will be used.

RSS icon

Sorin Group Starts First Randomized, Controlled Trial Comparing the Perceval Sutureless Valve to Standard Bioprostheses

Sorin Group, a global medical device company and a leader in the treatment of cardiovascular diseases, today announced the initiation of PERSIST-AVR (Perceval Sutureless Implant Vs Standard Aortic ValveReplacement), the first international, prospective, post-market randomized multi-center trial evaluating the Perceval sutureless aortic valve compared to standard sutured bioprostheses in patients with aortic valve disease.

Medtronic Receives CE Mark for New Single-Chamber ICDs That Can Detect Atrial Fibrillation

Medtronic plc (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark for the Visia AF(TM) and Visia AF MRI(TM) SureScan® single-chamber implantable cardioverter defibrillators (ICDs), which can detect and monitor new onset, asymptomatic, and previously undiagnosed atrial fibrillation (AF).

Medtronic Partners with Local Organizations and Minnesota Department of Health to Advance Health Equity in Minnesota

Medtronic (NYSE: MDT) today announced that Pillsbury United Communities, Regions Hospital Foundation and the HealthFinders Collaborative have been selected by Medtronic Philanthropy to implement the HealthRise U.S. program in Minnesota.

Abiomed's Impella(R) Technology Showcased at TCT 2015 With Over 25 Presentations in the Scientific Sessions

Abiomed Inc. (NASDAQ:ABMD), a leading provider of breakthrough heart support technologies, announces that there are currently over 25 presentations potentially featuring the Impella line of heart pumps, scheduled in the scientific sessions at the Cardiovascular Research Foundation's (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) 2015 scientific meeting, scheduled from October 11 - 15, at the Moscone Convention Center in San Francisco.

FORTITUDE Clinical Findings Presented at Transcatheter Cardiovascular Therapeutics Meeting

Amaranth Medical, a privately held medical device company, announced that enrollment has successfully concluded in its multi-center, international CE Mark clinical trials: MEND-II and RENASCENT-I, which assessed Amaranth's FORTITUDE(R) sirolimus-eluting bioresorbable scaffold (BRS) in patients with symptomatic coronary artery disease. 

Thumbnail

TCT.15: Drug-coated balloon is superior to PTA in patients with peripheral artery disease

After two years of follow up, patients with peripheral artery disease who received a drug-coated balloon had significantly higher primary patency and a significantly lower rate of clinically driven target lesion revascularization compared with patients who received conventional percutaneous transluminal angioplasty (PTA).

TCT.15: Fractional flow reserve estimated using CT reduces costs and resource utilization at 90 days

For patients with chest pain and no known coronary artery disease, an evaluation strategy based on fractional flow reserve estimated using CT (FFRCT) led to reduced costs within 90 days and less resource utilization compared with an invasive coronary angiography evaluation strategy.

Medtronic CoreValve® System Demonstrates Excellent Clinical Outcomes in First Report of 'Real-World' U.S. Experience

Medtronic plc (NYSE: MDT) today released the first CoreValve® Transcatheter Aortic Valve Replacement (TAVR) System outcomes data using CoreValve data from The Society of Thoracic Surgeons and American College of Cardiology (STS/ACC) Transcatheter Valve Therapy (TVT) Registry. 

Displaying 1673 - 1680 of 2645

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.